Recombinant CD19 (Tafasitamab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target
- CD19 (Tafasitamab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
- Host
-
Mammalian Cells
- Expression System
- Mammalian cells
- Clonality
- Monoclonal
- Application
- ELISA
- Purpose
- Tafasitamab Biosimilar - Anti-CD19 mAb
- Characteristics
- Antibody Type: IgG1-G2-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Grade
- Research Grade
- Isotype
- IgG1
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- CD19 (Tafasitamab Biosimilar)
- Target Type
- Biosimilar
- Background
-
MOR-00208,MOR-208,XENP-5574,XMP-5574,XmAb-5574,Xmab-CD19
Tafasitamab is a humanized monoclonal antibody that targets CD19. It is used for the treatment of B-cell malignancies. The CD19 surface protein is highly expressed on the surface of B-cells where it enhances B-cell receptor signaling. CD19 is especially expressed in cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL). By its activity, tafasatimab induces the lysis of B-cells. - CAS-No
- 1422527-84-1
-
You are here:
